HRP20050933A2 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
HRP20050933A2
HRP20050933A2 HR20050933A HRP20050933A HRP20050933A2 HR P20050933 A2 HRP20050933 A2 HR P20050933A2 HR 20050933 A HR20050933 A HR 20050933A HR P20050933 A HRP20050933 A HR P20050933A HR P20050933 A2 HRP20050933 A2 HR P20050933A2
Authority
HR
Croatia
Prior art keywords
organic compounds
compounds
zwitterions
muscarinic
receptor
Prior art date
Application number
HR20050933A
Other languages
English (en)
Croatian (hr)
Inventor
Paul Collingwood Stephen
Cox Brian
Baettig Urs
Bhalay Gurdip
James Devereux Nicholas
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33420896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050933(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0324887A external-priority patent/GB0324887D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20050933A2 publication Critical patent/HRP20050933A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20050933A 2003-05-02 2005-10-28 Organic compounds HRP20050933A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0310232 2003-05-02
GB0324887A GB0324887D0 (en) 2003-10-24 2003-10-24 Organic compounds
PCT/EP2004/004605 WO2004096800A2 (fr) 2003-05-02 2004-04-30 Composes organiques

Publications (1)

Publication Number Publication Date
HRP20050933A2 true HRP20050933A2 (en) 2006-12-31

Family

ID=33420896

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050933A HRP20050933A2 (en) 2003-05-02 2005-10-28 Organic compounds

Country Status (32)

Country Link
US (2) US20070060563A1 (fr)
EP (1) EP1631569B1 (fr)
JP (1) JP4416786B2 (fr)
KR (1) KR100896544B1 (fr)
AR (1) AR044134A1 (fr)
AT (1) ATE440840T1 (fr)
AU (1) AU2004234069B2 (fr)
BR (1) BRPI0410238A (fr)
CA (1) CA2523436C (fr)
CL (1) CL2004000918A1 (fr)
CO (1) CO5700782A2 (fr)
CY (1) CY1109655T1 (fr)
DE (1) DE602004022805D1 (fr)
DK (1) DK1631569T3 (fr)
EC (1) ECSP056134A (fr)
ES (1) ES2331185T3 (fr)
HK (1) HK1087704A1 (fr)
HR (1) HRP20050933A2 (fr)
IL (1) IL171591A (fr)
IS (1) IS2746B (fr)
MA (1) MA27775A1 (fr)
MX (1) MXPA05011739A (fr)
MY (1) MY142652A (fr)
NO (1) NO20055688L (fr)
NZ (1) NZ542995A (fr)
PE (1) PE20050465A1 (fr)
PL (1) PL1631569T3 (fr)
PT (1) PT1631569E (fr)
RU (1) RU2363700C2 (fr)
SI (1) SI1631569T1 (fr)
TW (1) TWI340139B (fr)
WO (1) WO2004096800A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428416D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1900737A1 (fr) * 2006-08-31 2008-03-19 Novartis AG Polymorphe de (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide
EP1894568A1 (fr) * 2006-08-31 2008-03-05 Novartis AG Composées pharmaceutiques destinées au traitement des maladies inflammatoires ou obstructives des bronches
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
CA2672446A1 (fr) * 2006-12-19 2008-06-26 Astrazeneca Ab Derives quinuclidinol utilises en tant qu'antagonistes du recepteur muscarinique
EP1950196A1 (fr) * 2007-01-29 2008-07-30 Boehringer Ingelheim Pharma GmbH & Co. KG Procédé de fabrication d'hexafluorophosphates d'ammonium
RU2480458C2 (ru) * 2007-09-07 2013-04-27 Тереванс, Инк. Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов
JP2011506477A (ja) 2007-12-14 2011-03-03 セラヴァンス， インコーポレーテッド ムスカリン受容体拮抗薬として有用なアミジン含有化合物
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
GB0808709D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
MX2010012019A (es) * 2008-05-13 2011-03-04 Astrazeneca Ab Producto farmaceutico que comprende un antagonista receptor muscarinico y un agonista de adrenoceptor beta2.
JP4837800B2 (ja) * 2008-05-13 2011-12-14 アストラゼネカ・アクチエボラーグ ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2009153536A1 (fr) * 2008-06-17 2009-12-23 Argenta Discovery Limited Dérivés de 1-aza-bicyclo [2.2.2] octane utiles en tant qu’antagonistes des récepteurs muscariniques
GB0811100D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination
WO2011161018A1 (fr) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dérivés aminoester d'alcaloïdes et compositions médicinales les comprenant
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
CA2828219A1 (fr) 2011-02-25 2012-08-30 Irm Llc Composes et compositions en tant qu'inhibiteurs de trk
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
EP2797910B1 (fr) * 2011-12-30 2015-09-16 Chiesi Farmaceutici S.p.A. Esters de quinuclidine et d'acide 1-azahétérocyclylacétique utilisés comme agents antimuscariniques, procédé pour leur préparation et compositions médicinales correspondantes
US9687488B2 (en) 2012-05-03 2017-06-27 St. Louis College Of Pharmacy Compositions and methods for increasing neurotrophic peptides
TWI647227B (zh) * 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 ２－醯胺噻唑衍生物或其鹽
CZ306791B6 (cs) 2013-10-29 2017-07-12 Zentiva, K.S. Průmyslově využitelný způsob přípravy aklidinium bromidu o vysoké čistotě
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
EP3111978B1 (fr) 2015-07-03 2021-09-01 Novartis AG Inhalateur conçu pour lire des informations stockées dans un dispositif de stockage de données d'un récipient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
DK534178A (da) * 1977-12-16 1979-06-17 Interx Research Corp Anticholinerge midler med sektrtionshaemmende virkning
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6846835B2 (en) * 2000-07-11 2005-01-25 Banyu Pharmaceutical Co., Ltd. Ester derivatives
AU2002238471B2 (en) * 2000-12-28 2007-06-28 Almirall, S.A. Quinuclidine derivatives and their use as M3 antagonists
KR100944580B1 (ko) * 2001-12-20 2010-02-25 치에시 파마슈티시 에스.피.아. 1-알킬-1-아조니아비시클로[2.2.2]옥탄 카르바메이트유도체 및 이의 무스카린 수용체 길항제로서의 용도
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
EP1900737A1 (fr) * 2006-08-31 2008-03-19 Novartis AG Polymorphe de (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide

Also Published As

Publication number Publication date
IS2746B (is) 2011-08-15
HK1087704A1 (en) 2006-10-20
SI1631569T1 (sl) 2010-01-29
US20100041887A1 (en) 2010-02-18
PL1631569T3 (pl) 2010-02-26
KR100896544B1 (ko) 2009-05-07
ATE440840T1 (de) 2009-09-15
DK1631569T3 (da) 2009-11-23
WO2004096800A2 (fr) 2004-11-11
AU2004234069A1 (en) 2004-11-11
AR044134A1 (es) 2005-08-24
PE20050465A1 (es) 2005-07-18
CA2523436A1 (fr) 2004-11-11
EP1631569B1 (fr) 2009-08-26
MXPA05011739A (es) 2006-01-26
EP1631569A2 (fr) 2006-03-08
NZ542995A (en) 2009-02-28
RU2363700C2 (ru) 2009-08-10
US8168654B2 (en) 2012-05-01
DE602004022805D1 (de) 2009-10-08
CL2004000918A1 (es) 2005-02-11
KR20060015572A (ko) 2006-02-17
PT1631569E (pt) 2009-11-26
ES2331185T3 (es) 2009-12-23
CA2523436C (fr) 2011-11-01
JP2006525267A (ja) 2006-11-09
RU2005137360A (ru) 2006-07-27
CY1109655T1 (el) 2014-08-13
TW200505920A (en) 2005-02-16
JP4416786B2 (ja) 2010-02-17
WO2004096800A3 (fr) 2005-01-06
IS8158A (is) 2005-11-30
NO20055688D0 (no) 2005-12-01
MY142652A (en) 2010-12-15
ECSP056134A (es) 2006-04-19
CO5700782A2 (es) 2006-11-30
IL171591A (en) 2010-11-30
TWI340139B (en) 2011-04-11
NO20055688L (no) 2006-01-09
AU2004234069B2 (en) 2008-02-21
BRPI0410238A (pt) 2006-05-16
US20070060563A1 (en) 2007-03-15
MA27775A1 (fr) 2006-02-01

Similar Documents

Publication Publication Date Title
HRP20050933A2 (en) Organic compounds
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
ES2368594T3 (es) Derivados sustituidos de ciclohexilmetilo.
BRPI0519292A2 (pt) compostos orgÂnicos
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TW200519106A (en) Organic compounds
SE0401971D0 (sv) Piperidne derivatives
ATE411296T1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung
MEP36508A (en) Triazolopyrazine derivatives useful as anti-cancer agents
BRPI0406762A (pt) Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça
WO2007084595A3 (fr) Benzènesulfonyle-chromane, thiochromane, tétrahydronaphthalène et inhibiteurs de la gamma secrétase associés
ATE541839T1 (de) Pyrrolidiniumderivate als m3-muskarinische rezeptoren
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
EA200702375A1 (ru) Производные мочевины, способы их получения и применения
SE0403171D0 (sv) New compounds
SE0401970D0 (sv) Novel compounds
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
SE0302139D0 (sv) Novel compounds
WO2009055629A3 (fr) Antagonistes trpv1
SE0303541D0 (sv) New compounds
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
MXPA05013823A (es) Derivados de pirrolidinio y piperidino como ligandos para el receptor m3 muscarinico.
SE0303280D0 (sv) Novel compounds
ATE455095T1 (de) Vanilloidrezeptor trpv1-antagonisten

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110423

Year of fee payment: 8

OBST Application withdrawn